Trial Profile
Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome; Neuroendocrine tumours
- Focus Pharmacokinetics
- 04 May 2023 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2023.
- 30 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Oct 2023.
- 30 Mar 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Oct 2022.